Neoplasms, Colorectal research hub

A Phase 1/2 open-label, multicenter study of oral GSK5460025 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors.

This study is testing a new medicine, GSK5460025, for adults with certain solid cancers, including bowel cancer. It's looking at whether the medicine is safe and if it can shrink tumours.